Drug Overview: NeoRecormon

  • ID: 4462219
  • Drug Pipelines
  • 8 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

NeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in chronic kidney disease (CKD). The drug consists of recombinant human erythropoietin and targets the erythropoietin receptor, initiating the same pathway as native erythropoietin and triggering increased blood production in bone marrow (EMC, 2017). NeoRecormon is comparable to Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) in terms of its clinical profile, with similar safety, efficacy, and dosing.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
NeoRecormon: Anemia in chronic kidney disease

List of Figures
Figure 1: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015-24

List of Tables
Table 1: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015-24
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll